Contemporary management of pediatric heart failure

References

• Galbreath AD, Krasuski RA, Smith B et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation110, 3518–3526 (2004).
   PubMed Web of Science ®Google Scholar
• Kannel WB. Incidence and epidemiology of heart failure. Heart Failure Rev.5, 167–173 (2000).
   PubMedGoogle Scholar
• Lipshultz SE, Sleeper LA, Towbin JA et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med.348, 1647–1655 (2003).
   PubMed Web of Science ®Google Scholar
• Nugent AW, Daubeney PEF, Chondros P et al. The epidemiology of childhood cardiomyopathy in Australia. N. Engl. J. Med.348, 1639–1646 (2003).
   PubMed Web of Science ®Google Scholar
• Katz AM. Heart Failure. In: Pathophysiology, Molecular Biology and Clinical Management. Lippincott, Williams & Wilkins, PA, USA, xiii (2000).
   Google Scholar
• Francis GS, McDonald K, Chu C, Cohn JN. Pathophysiologic aspects of end-stage heart failure. Am. J. Cardiol.75, 11A–18A, (1995).
   Google Scholar
• Fenton M, Burch M. Understanding chronic heart failure. Arch. Dis. Child.92, 812–816 (2007).
   Google Scholar
• Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation111, 2837–2849 (2005).
   PubMed Web of Science ®Google Scholar
• Mir TS, Maroh S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentration of N-terminal and pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics110, e76, (2002).
   PubMedGoogle Scholar
• Guimaraes GV, Bellotti G, Mocelin AO et al. Cardiopulmonary exercise testing in children with heart failure secondary to idiopathic dilated cardiomyopathy. Chest120, 816–824 (2001).
   Google Scholar
• Ross RD, Bollinger RO, Pinsky WW. Grading the severity of heart failure in Infants. Pediatr. Cardiol.13, 72–75 (1992).
   Web of Science ®Google Scholar
• Johnstone DE, Abdulla A, Arnold JM et al. Diagnosis and management of heart failure. Canadian Cardiovascular Society. Can. J. Cardiol.10, 613–631 (1994).
   Web of Science ®Google Scholar
• Connolly D, Rutkowski M, Auslender M, Artman M. The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J. Pediatr.138, 644–648 (2001).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol.38, 2101–21013 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenthal D, Chrisant MRK, Edens E et al. International Society for Heart and Lung Transplantation: Practice Guidelines for Management of Heart Failure in Children. J. Heart Lung Transplant.23, 1313–1333 (2004).
   PubMed Web of Science ®Google Scholar
• Haykowsky MJ, Liang Y, Pechter D et al. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: The benefit depends on the type of training performed. J. Am. Coll. Cardiol.49, 2329–2336 (2007).
   PubMed Web of Science ®Google Scholar
• Blume ED, Freed MD, Colan SD. Congestive Heart Failure. In: Nadas’ Pediatric Cardiology, 2nd Edition. Keane JF, Lock JE Fyler DC (Eds). Saunders Elsevier Publishers, PA, 83–95 (2006).
   Google Scholar
• `Moffett BS and Chang AC. Future pharmacologic agents for treatment of heart failure in children. Pediatr. Cardiol.27, 533–551 (2006).
   PubMedGoogle Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N. Engl. J. Med.316, 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med.325, 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation100, 2312–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr. Cardiol.14, 9–12 (1993).
   PubMed Web of Science ®Google Scholar
• Lin M, Chiang HT, Lin SL et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J. Am. Coll. Cardiol.24, 1046–1053 (1994).
   PubMedGoogle Scholar
• Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N. Engl. J. Med.353, 1342–1349 (2005).
   PubMed Web of Science ®Google Scholar
• Mori Y, Nakazawa M, Tomimatsu H, Momma K. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J. Am. Coll. Cardiol.36, 270–275 (2000).
   PubMedGoogle Scholar
• Rheuban KS, Carpenter MA, Ayers CA, Gutgesell HP. Acute hemodynamic effects of converting enzyme inhibition in infants with congestive heart failure. J. Pediatr.117, 668–670 (1990).
   Google Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation103, 904–912 (2001).
   PubMed Web of Science ®Google Scholar
• Jong P, Demers, C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol.39, 463–470 (2002).
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Salukhe TV, Coats AJS, Mayet J, Piepoli M, Francis DP. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int. J. Cardiol.93, 105–111 (2004).
   Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA283, 1295–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med.344, 1651–1658 (2001).
   PubMed Web of Science ®Google Scholar
• Shaddy RE, Tani LY, Gidding SS et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J. Heart Lung Transplant.18, 269–274 (1999).
   PubMed Web of Science ®Google Scholar
• Bruns LA, Chrisant MK, Lamour JM et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J. Pediatr.138, 505–511 (2001).
   PubMed Web of Science ®Google Scholar
• Shaddy RE, Boucek MM, Hsu DT et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA298, 1171–1179 (2007).
   PubMed Web of Science ®Google Scholar
• Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation96, 1507–1512 (1997).
   PubMed Web of Science ®Google Scholar
• Dore A, Houde C, Chan KL et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation112, 2411–2416 (2005).
   PubMed Web of Science ®Google Scholar
• Laer S, Mir TS, Behn F et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am. Heart J.145, 916–922 (2002).
   Google Scholar
• Gidding SS. The importance of randomized controlled trials in pediatric cardiology. JAMA298, 1214–1216, (2007).
   Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation112, e154–e235 (2005).
   Google Scholar
• Mano A, Tatsumi T, Shiraishi J et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation110, 317–323 (2004).
   PubMedGoogle Scholar
• MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struther AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart82, 57–61 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad P, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med.341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med.348, 1309–1321 (2003).
   PubMed Web of Science ®Google Scholar
• Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation80, 65–77 (1989).
   PubMed Web of Science ®Google Scholar
• Covit AB, Schaer Gl, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am. J. Med.75, 445–447 (1983).
   PubMed Web of Science ®Google Scholar
• The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med.336, 525–533 (1997).
   PubMed Web of Science ®Google Scholar
• Kimball TR, Daniels SR, Meyer et al. Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am. J. Cardiol.68, 1377–1382 (1991).
   PubMed Web of Science ®Google Scholar
• Latifi S, Lidsky K, Blumer JL. Pharmacology of inotropic agents in infants and children. Prog. Pediatr. Cardiol.12, 57–79 (2000).
   PubMedGoogle Scholar
• Hoffman TM, Wernovsky G, Atz AM et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation107, 996–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Habib DM, Padbury JF, Anas NG, Perkin RM, Minegar C. Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit. Care Med.20, 601–608 (1992).
   PubMed Web of Science ®Google Scholar
• Wessel DL. Testing new drugs for heart failure in children. Pediatr. Crit. Care Med.7, 493–494 (2006).
   Google Scholar
• Publication Committee for the VMAC Investigators. Intravenous nesiritide vs Nitroglycerin for treatment of decompensated congestive heart failure; a randomized controlled trial. JAMA287, 1531–1540 (2002).
   PubMed Web of Science ®Google Scholar
• Mahle WT, Cuadrado AR, Kirshom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. Pediatr. Crit. Care Med.6, 543–546 (2005).
   PubMedGoogle Scholar
• Tassani P, Schad H, Heimisch W et al. Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetized pigs. Cardiovasc. Drugs Ther.16, 35–41 (2002).
   Google Scholar
• Adamopoulos S, Parissis JT, Iliodromitis EK et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am. J. Cardiol.98, 102–206 (2006).
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JGF, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet360, 196–202 (2002).
   PubMed Web of Science ®Google Scholar
• Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS. Early experience with levosimendan in children with ventricular dysfunction. Pediatr. Crit. Care Med.7, 445–448 (2006).
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA297, 1883–1891 (2007).
   PubMed Web of Science ®Google Scholar
• Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA289, 2685–2694 (2003).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med.350, 2140–2150 (2004).
   PubMed Web of Science ®Google Scholar
• Dubin AM, Janousek J, Rhee E et al. Resynchronization therapy in pediatric and congenital heart disease patients. J. Am. Coll. Cardiol.46, 2277–2283 (2005).
   PubMed Web of Science ®Google Scholar
• Potapov EV, Stiller B, Hetzer R. Ventricular assist devices in children: current achievements and future perspectives. Pediatr. Transplantation11, 241–155 (2007).
   Google Scholar
• Boucek MM, Edwards LB, Keck BM et al. Registry for the International Society for Heart and Lung Transplantation: seventh official pediatric report 2004. J. Heart Lung Transplant.23, 933–947 (2004).
   Google Scholar
• Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J. Am. Coll. Cardiol.39, 1414–1421 (2002).
   PubMed Web of Science ®Google Scholar